Filing Flows › Sarepta Therapeutics (SRPT) › Free cash flow
Sarepta Therapeutics (SRPT) free cash flow by quarter
Sarepta Therapeutics' free cash flow was $57.0M in Q3 2026 (third quarter 2026), -71% from Q2 2026. Over the last 4 quarters it ranged from $57.0M (Q3 2026) to $230M (Q2 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $57.0M | -71% | — |
| Q2 2026 | $197M | +54% | -14% |
| Q4 2025 | $128M | -44% | — |
| Q2 2025 | $230M | — | — |
Q3 2026 at a glance
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sarepta Therapeutics' free cash flow?
Sarepta Therapeutics' free cash flow was $57.0M in Q3 2026 (third quarter 2026), -71% from Q2 2026.
How has Sarepta Therapeutics' free cash flow changed?
Over the last 4 quarters it ranged from $57.0M (Q3 2026) to $230M (Q2 2025).